CD3 closes 60 million euro fund to turn academic research into new medicines.
The Centre for Drug Design & Discovery (CD3) has launched a 60 million euro fund to turn innovative biomedical research of academic institutions and small companies into drugs that improve and extend people’s lives. Following on previous investments in 2006 and 2010, KU Leuven Research & Development and the European Investment Fund (EIF) jointly provide the capital for this third CD3 fund. Both partners thereby strongly confirm their belief in CD3’s mission to translate innovative (academic) science into promising drug discovery programs that are well qualified for further development by pharmaceutical or biotech companies. The new fund will allow CD3 to bring potential drugs into clinical development together with industrial partners, as well as on its own.
Cistim job vacancies
Are you looking for a job in the field of drug discovery? Cistim has three vacancies that might interest you. Check out the Cistim website for more information.
University of Turku and CD3 Sign Strategic Cancer Drug Development Agreement
15/07/2015 - The University of Turku in Finland and the Centre for Drug Design and Discovery (CD3) of the University of Leuven in Belgium announced the signing of a collaboration agreement for the development of a new type of cancer drug.
Deal with Novartis for the development of new rhinovirus inhibitors.
VIB and CD3 join forces with AstraZeneca for the development of MALT1 inhibitors
VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.
Wellcome Trust and KU Leuven collaborate with Janssen for development of dengue antiviral drugs
Researchers at the University of Leuven (KU Leuven) are joining forces with Janssen Pharmaceuticals Inc. (Janssen) and the Wellcome Trust to discover and develop candidate antiviral drugs for the prevention and treatment of dengue infection.